Drugs cost too much. There is a better way to fund medical innovation

Drugs Medicine 2018 United Nations

UNICEF/Olivier Asselin In Côte d’Ivoire, a counsellor from UNICEF partner NGO Femme Active, instructs an adolescent boy, diagnosed with HIV in 2012, on how to take his antiretroviral (ARV) medication correctly.

This article is brought to you based on the strategic cooperation of The European Sting with the World Economic Forum.

Author: Rufus Pollock, Lead, iMed Project, and Founder and President of Open Knowledge

Drugs are expensive. Very expensive, and becoming ever more so, it seems. Prices for new medicines have been steadily rising for the past few decades. It costs a great deal to bring new drugs to market, the explanation goes, and without high prices, the pipeline of new medicines will run dry.

This argument is unsustainable, especially when even the world’s most developed economies and healthcare systems are struggling to afford vital medicines. To keep paying more for drugs simply cannot be the answer. Bad health affects everyone. We should be urgently seeking new mechanisms of funding medical innovation that do not compromise on access.

There is a strong moral and social obligation for exploring alternatives. Millions of people globally do not have access to the medicines they need to survive. In the US, millions of adults skip prescribed medications due to the high cost. The same is true in Canada, where the public healthcare system does not usually extend to cover prescription medicines, and in Europe, especially in poorer members of the EU.

The situation is worse in less developed countries. Many pay out of pocket for drugs, and the hefty price tags can run many times the annual average income. Two widely used drugs for treating hepatitis C cost the equivalent of one or more years’ average earnings in 12 out of 30 countries, revealed a recent study by the World Health Organization. Millions are dying because they cannot afford the medicine they need to stay alive.

When some members of society lack medicine, there are consequences beyond the individual directly affected. The increased morbidity caused by a lack of access to medication places an extraordinary strain on healthcare systems, exacerbating the drain on their resources from ever more expensive drugs. In addition, unhealthy populations are far less economically productive than healthy ones. Beyond social justice, there are clear economic reasons to find new models of funding medical innovation that do not restrict access to medicine.

The current state of affairs is making the world a more dangerous place. Healthcare systems that are strained by increased morbidity, and by a critical lack of money and medicine, are less likely to be able to contain outbreaks when they occur. Poor global health increases global instability. Failing to ensure everyone has access to necessary medication can have profound knock-on consequences and worsen existing crises.

Moreover, the high sale price of drugs skews incentives for innovation towards wealthy consumers. This means that vital medicines for certain ailments are not accessible when needed on a global scale. For instance, the Ebola virus had been known about for decades before the recent outbreak, and yet virtually no treatments were available. The whole world is unprepared and at risk.

The explanation that pharmaceutical companies offer for high drug prices is compelling. It costs a great deal of money to bring a drug to market, they argue. This is why so many reluctantly accept the current state of affairs, in which innovation justifies restricted access. Though it is true that drugs do cost a lot to bring to market, there is a remarkable lack of consensus on exactly how much.

This is compounded by a systemic lack of transparency. It is often not known how much is spent on what, and how reliant private-sector developments are on publicly funded research. Often, medicines that are developed with significant help from public funds do not reflect that support in prices, and there is no guarantee under the monopoly rights patent system that they should.

Moreover, a great deal of money that could be earmarked for research is spent on marketing instead. Indeed, in some large drug companies, expenditure on marketing outweighs that on research.

This model is unsustainable. So long as we continue to reward innovation through a single channel – buying the drug – access to new medicines will be limited. Ultimately, the problem is about how we pay for medicine. Today, we only pay by purchasing the end product. This means that the costs of manufacture (which is cheap) and innovation (which is expensive) are rolled into one. This puts access and innovation in conflict.

If we were to change how we fund medicines, there could be no conflict. Incentives for innovation and access to affordable drugs could co-exist. We can fund research and production separately. There is no excuse for not exploring the wide systemic changes needed to make that happen.

Today’s model is unsustainable, unhealthy and utterly unnecessary. We can have new medicines and wide access to them. We should be working towards this as a matter of urgency.

And we have ideas. For example, at the iMed Project we’ve been developing innovative two-part payment models for funding medicines that would maintain incentives for innovators while making treatment at cost of manufacture.”

Advertising

Advertising

Advertising

Advertising

Featured Stings

Stopping antimicrobial resistance would cost just USD 2 per person a year

Kellen Europe Hosts EuroConference 2016

JADE @ European Business Summit 2014: Youth Unemployment – a drive to Entrepreneurship

Volkswagen getting away with it in Europe

3 reasons why AI won’t replace human translators… yet

Stigmatized, shunned and shamed, International Widows’ Day draws attention to their unique needs

Connected Claims returns to London in 2018

Philippe de Backer of ALDE at European Business Summit 2015 stresses: “Reinvent your business”

EU economy: Between recession and indiscernible growth

Parallel downfalls of Merkel and Deutsche Bank threaten Germany and Europe

Eurozone very close to a sustainable growth path

US, Russia oblige each other in Syria and Ukraine selling off allies

Draghi keeps the euro cheap, helps debt refinancing, recapitalization of banks and growth

Medschool 4.0: how to succeed in the smart revolution of healthcare

The Italian ‘no’ and France’s Fillon to reshape Europe; Paris moves closer to Berlin

80,000 youngsters at risk in DRC after forcible expulsion from Angola: UNICEF

Heat-resistant crops, ‘green’ infrastructure, can prepare Near East and North Africa to better tackle droughts – UN agency

European Commission requests that Italy presents a revised draft budgetary plan for 2019

Who cares more about taxpayers? The US by being harsh on major banks or the EU still caressing them?

Mobile 360 Series – Russia & CIS: Empowering the Digital Economy

Why are the Balkans’ political leaders meeting in Geneva this week?

Charges against Baha’i in Yemen must be dropped: UN experts urge release of detainees

High level political talks didn’t break the stalemate in Ukraine

Eurostat overturns Commission’s assessment of the economy

New rules for audiovisual media services approved by Parliament

French full-body veil ban, violated women’s freedom of religion: UN Human Rights Committee

European Youth calls on European Council for urgent action on “humanitarian crisis” and questions the EU/Turkey deal respect of human rights

It’s time to end our ‘separate but unequal’ approach to mental health

Armed groups threaten every child in Central African Republic, UNICEF warns

Are the G20 leaders ready to curb corporate tax-avoidance?

Will CETA be implemented after eight long years or it will be vetoed by the EU citizen?

Economic sentiment and business climate stagnate in miserable euro area

The Bavarians threaten Berlin and Brussels with immigration crisis

10 months were not enough for the EU to save the environment but 2 days are

Eurozone economy desperately needs internally driven growth

How can education empower youth to become tomorrow’s leaders

EU Parliament and Council: Close to agreement on the bank resolution mechanism

Virtual Doctor: a core part of modern healthcare?

Food supply chain: A step closer to ending unfair trading

UN chief calls for ‘solidarity, compassion and action’ on World Refugee Day

How to future-proof India’s economy

‘Unconscionable’ to kill aid workers, civilians: UN Emergency Coordinator

Will Brexit shatter the EU or is it still too early to predict?

“A global threat lies ahead worsened after the EU’s green light to the Bayer-Monsanto merger”, a Sting Exclusive by the President of Slow Food

IMF v Germany: Eurogroup keeps the fight under control

How will the EU face the migration crisis when the Turkish threats come true?

Parliament backs a modernised EU electoral law

How will EU look after French, Dutch and German Elections and what will be the implications for Youth Entrepreneurship?

European Youth, quo vadis?

‘Staunch support’ for Iran nuclear deal tempered by concern over missile testing

Indoor air pollution is deadly. Here’s an unconventional solution

The EU has to prove it can remain one piece

Pharmaceuticals conceal drug side effects with the EU’s Court blessing

Can we balance conservation and development? Science says yes

Commission proposes fishing opportunities in the Atlantic and North Sea for 2019

Eurogroup: IMF proposes Germany disposes

A Sting Exclusive: “Regulators and the shipping industry collaborating for a sustainable future”, written by the Secretary General of IMO

Global Talent – Professional Internships

8 amazing facts to help you understand China today

ECB should offer more and cheaper liquidity if Eurozone is to avoid recession

AIDEX 2015: Humanitarian Hero Award Winner Announced

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s